



De Novo Selection of Peptides That Confer Antibiotic Resistance

Michael Knopp and Dan I. Andersson



UPPSALA
UNIVERSITET

Department of Medical Biochemistry and Microbiology
Uppsala University, Sweden



Question

How can new genes originate *de novo* (from random DNA sequences)?



Conclusion

- Random sequences can encode functional peptides at a frequency that can be experimentally assessed
- These peptides confer resistance levels similar to chromosomal mutations
- The resistance mechanisms rely on pre-existing cellular functions
- The isolated peptides are highly hydrophobic and are predicted to interact with the membrane

Library construction


name	size (aa)	diversity (x10 ⁶)	sequence	#Stop	bias
rnd 10	10	1.34	..(NNB)..	1	none
rnd 20	20	1.42	..(NNB)..	1	none
rnd 50a	50	1.71	..(NNB)..	1	none
rnd 50b	50	1.04	..(VNY)..	0	primordial
rnd 50c	50	0.31	..(XXX)..	<1	hydrophilic

N: A 25%, G 25%, C 25%, T 25% Y: C 50%, T 50% X: G 50%, C 22%, T 22%
B: G 50%, C 25%, T 25% Y: A 30%, G 31%, C 25%, T 14%
V: A 33%, G 33%, C 33% X: A 41%, G 23%, C 25%, T 11%


RBS: P_{LacO} ATG randomized sequence STOP terminator

Plasmid: pRD2 low copy, MCS, p15A, p15A, p15A, p15A

Transformation



Selection



Characterization

Is the phenotype caused by the mRNA or the encoded peptide?

Is the phenotype limited to the expression system, plasmid and/or strain selected in?

How does the resistance level compare to spontaneous resistance mutants?

What is the mechanism of action?


Experimental Set-Up

Aminoglycoside Resistance

Results


Colistin Resistance

Sequence analysis




All three identified peptides (Arp1-3) are short, highly hydrophobic and predicted to be transmembrane helices


Site-directed mutagenesis




In vitro membrane depolarization




Cross-resistance




Additivity with chromosomal mutants




In vivo membrane depolarization




- Colistin is a last-resort antibiotic for treatment of multi-drug resistant *Pseudomonas*, *Klebsiella* and *Acinetobacter* species
- Resistant mutants typically show an overactivation of the PmrAB two-component system resulting in Lipid A modifications
- Only one plasmid-borne resistance gene has been described (*mcr*), an enzyme that also causes Lipid A modifications



TLC of lipid A



Whole-cell proteome analysis



COLLABORATORS:

Fredrika Rajer¹ Jonina Gudmundsdottir³
Omar Warsi¹ Pia Ädelroth⁴
Stephen M. Trent² Finja König⁴
Martin V. Douglass² Tobias Nilsson⁴

(1) Uppsala University
(2) University of Georgia
(3) University of Tromsø
(4) Stockholm University

REFERENCE:

Knopp M., Gudmundsdottir JS., Nilsson T., König F., Warsi O., Rajer F., Ädelroth P., Andersson DI. (2019) *De novo* emergence of peptides that confer antibiotic resistance. *mBio*

CONTACT:

Mail: Michael.Knopp@imbim.uu.se